MDS Anemia - EPO/GCSF Response

Identify those with MDS likely to respond to stem-cell factors.

Questions

1.Serum Erythropoietin?
2.Transfusion needs?

About

In general, treatment with erythropoietin (EPO) may improve anemia in about 15-20% of patients with myelodysplastic syndromes (MDS). The combination of EPO and granulocyte colony-stimulating factor (GCSF) may improve response rates to ~40%. This predictive model uses two variables (serum EPO and transfusion need) to identify those who are most likely to respond to these stem-cell factors. The model was developed and validated predominantly in patients with low-risk MDS. Response is defined as a 100% reduction in RBC transfusion need or an increase in hemoglobin level by at least 1.5 g/L.

Created by on 30/12/2015

By using this site you acknowledge that you have read, understand, and agree to be bound by our terms of use and privacy policy. All content and tools are for educational use only, are not meant to be a substitute for professional advice and should not be used for medical diagnosis and/or medical treatment.

1. Serum Erythropoietin?

0/2 completed